More evidence presented by clinical studies: “Dr Michael Biggs (an advisor to SEGM) has been calling for the release of data from the Tavistock’s experiment since
2019. A subset of the data were finally released following the
judicial review into puberty suppression at the Tavistock clinic. Biggs’ reanalysis has just been published in the
Journal of Paediatric Endocrinology and Metabolism.
It finds that after two years on GnRHa, the Z-scores for a significant minority of the children had declined to a level that should trigger clinical concern. For the hip, one third of Z-scores were below -2. For the spine, over a quarter of Z-scores were below the threshold of -2. Some had even fallen below ‑3; such low bone density is found in only 0.13% of the population.”
“The rapid rise in bone mineral density normally in adolescence is critical for maximising the peak bone mass of early adulthood that acts as a key mitigant against osteoporosis and fractures. Any loss of bone mineral density in adolescence is abnormal and may compromise peak bone mass.
That most trans and gender diverse adolescents lose bone mass is therefore concerning.”
Cohen and Barnes clearly articulate the ongoing debate on the effects of puberty blockers (gonadotrophin releasing hormone (GnRH) agonists) on bone mineral density in trans and gender diverse young people.1 Contention remains as to whether use of GnRH agonists in adolescents causes slow bone...
www.bmj.com
The above studies are not unique by any means. Readers can find many reputable sources to support the medical findings above.